A new era of HIV prevention is upon us. Pharmaceutical company Gilead Sciences Canada recently announced it is seeking approval from Health Canada for the use of Truvada as Pre-Exposure Prophylaxis. Better known as PrEP, the new highly effective prevention tool is now on track to be available in Canada.
My work as a scientist involves researching the potential impact of cannabis among people living with HIV/AIDS. Patients have told us for decades that marijuana helps them deal with the side effects of their medications. But now, in a preliminary study, we have found evidence to suggest that people who use cannabis are more likely to have slower HIV disease progression -- meaning that they can live longer and healthier lives.
Conversations about cannabis policy are heating up. So it's no surprise that we suddenly seem immersed in claims and counterclaims on a slew of topics related to cannabis use and regulation. The International Centre for Science in Drug Policy has tasked itself with determining the strength of scientific support for such claims. Over the past year, we've been working diligently on scanning the news media and online conversations about cannabis to identify the most oft-repeated or high-profile claims including the ones above related to its use and regulation.
Attend an all candidate's meeting in your area, and ask what his or her stance is on GMOs. If enough people ask, they'll know that this is important to Canadians, and that their chances of getting elected will depend on where they stand on this issue! Together, we can make GMO labelling an election issue.